Spencer Pharmaceutical (SPPH)

[$on_myMind]

In 2006, global sales of the AD drugs were worth some US$ 1.6 billion. The Alzheimer’s drugs are relatively expensive medicines (costing around $1,700 to $2,300 per year for the patient). They can cause side effects however and these outweigh the sometimes limited benefits and lead to the end of the treatment. Thus, a new drug or strategy such as the one that INSA has developed with no side effects and good benefits would be a real advantage to the patient. "